Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells

Fully human anti-CD19 and CD22 bispecific tandem CAR-TПодробнее

Anti CD22 CAR T cell therapy for relapsed paediatric ALLПодробнее

Efficacy of bispecific CD19/CD22 CAR T-cells in B-cell malignanciesПодробнее

Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 statusПодробнее

CD19- and CD22-Directed Chimeric Antigen Receptor T-Cell Therapy in Childhood B-Cell ALLПодробнее

Phase I study of CD22-targeted CAR-T therapy in patients with CD19-negative B-ALLПодробнее

CIPO2015: Dual Targeting of CD19 & CD22 on B-ALL Using a Single Bispecific Chimeric Antigen ReceptorПодробнее

Humanized versus murinized CD19/CD22 CAR-T cell therapy for R/R B-cell lymphomaПодробнее

Advancements and challenges in CAR-T cell therapyПодробнее

Anti-CD22 CAR T-cells shift ALL into complete remissionПодробнее

Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with relapsed/refracto...Подробнее

CD19 CAR T-cells for adultsПодробнее

Dr. Shah on Differences Between Anti–CD19 CAR T-Cell TherapiesПодробнее

CAR-T therapy in pediatric and adult ALLПодробнее

Advances in CD22/CD19 CAR-T sequential therapyПодробнее

Phase I study of CD22 CAR-T therapy in patients with LBCL who have relapsed after CD19 CAR-T therapyПодробнее

Anti-CD20/19 CAR-T cell therapy in r/r B-cell malignanciesПодробнее

CD19 CAR T Cell Therapy for Pediatric ALL: The Seattle Children’s ExperienceПодробнее

Developing the next generation of CAR-T cellsПодробнее